title: Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
abstract: Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
authors.affiliation: Unité d'Immunologie-Hématologie et Rhumatologie Pédiatrique, Hôpital Necker-Enfants Malades, 75 743 Paris cedex 15, France. quartier@necker.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Quartier
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.forename: Christine
authors.initials: C
authors.lastname: Archimbaud
authors.forename: Leila
authors.initials: L
authors.lastname: Lazaro
authors.forename: Carine
authors.initials: C
authors.lastname: Chaleteix
authors.forename: Pascale
authors.initials: P
authors.lastname: Millet
authors.forename: Hélène
authors.initials: H
authors.lastname: Peigue-Lafeuille
authors.forename: Stéphane
authors.initials: S
authors.lastname: Blanche
authors.forename: Alain
authors.initials: A
authors.lastname: Fischer
authors.forename: Jean-Laurent
authors.initials: JL
authors.lastname: Casanova
authors.forename: Philippe
authors.initials: P
authors.lastname: Travade
authors.forename: Marc
authors.initials: M
authors.lastname: Tardieu
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D008590:Meningoencephalitis / Q000139:chemically induced*; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab